HIV Infection-Related Cachexia and Lipodystrophy

  • Daniele Scevola
  • Angela Di Matteo
  • Omar Giglio
  • Filippo Uberti


Protein energy malnutrition (PEM) is, alone or associated with other diseases, the first step in the development of cachexia [1] [3]. An insufficient amount of food is the leading cause of malnutrition and infectious diseases are the second. In developing countries, 20% of the population — more than 800 million people — eats a quantity of food only sufficient to supply energy for a sedentary life, i.e. 1.2–1.4 times the resting energy expenditure (REE).More than 192 million children suffer from PEM and 2 billion people lack different micronutrients (vitamins, minerals, essential fatty and amino-acids) [4] [7]. Even in Western countries, where an enormous surplus of food is produced, many groups of people, especially the poor, the elderly, drug addicts, pregnant women, patients with liver, kidney and gastro-intestinal (GI)-tract diseases, cancer, AIDS, show nutritional defects. In general, 60% of the world’s population (41% in developing countries) consumes less than 2600 Kcal/person/day, an amount of energy considered barely sufficient for limited activity.


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Brown Adipose Tissue Human Immunodeficiency Virus Patient Rest Energy Expenditure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Torun B, Viteri FE (1988) Protein-energy malnutrition. In: Shils ME, Young VR (eds) Modern nutrition in health and disease, 7th edn. Lea & Febiger, Philadelphia, pp 746–773Google Scholar
  2. 2.
    Scevola D (1993) La cachessia nelle malattie infettive e neoplastiche. Edizioni Medico Scientifiche, PaviaGoogle Scholar
  3. 3.
    Watson RR (1994) Nutrition and AIDS. CRC Press, Boca RatonGoogle Scholar
  4. 4.
    Anonymous (1986) WHO: Working group on the use and interpretation of anthropométric indicators of nutritional status. Bull World Health Organ 64:929–941Google Scholar
  5. 5.
    Anonymous (1991) World population prospects 1990. United Nations, New YorkGoogle Scholar
  6. 6.
    Anonymous (1992) Health and health-related problems. WHO, GenevaGoogle Scholar
  7. 7.
    Anonymous (1992) Scope and dimension of nutrition problems. WHO, GenevaGoogle Scholar
  8. 8.
    Bruera E, Higginson I (1996) Cachexia-anorexia in cancer patients. Oxford University Press, OxfordGoogle Scholar
  9. 9.
    Center for the Disease Control (1987) CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 36(Suppl 1):3S–15SGoogle Scholar
  10. 10.
    Dworkin B, Wormser GP, Rosenthal WS et al (1985) Gastrointestinal manifestations of the acquired immunodeficiency syndrome: a review of 22 cases. Am J Gastr 8:774–778Google Scholar
  11. 11.
    Anonymous (1989) Malnutrition and weight loss in patients with AIDS. Nutr Rev 11:354–356Google Scholar
  12. 12.
    Anonymous (1989) HIV-associated enteropathy. Lancet 2:777–778Google Scholar
  13. 13.
    Scevola D (1989) Malattie infettive nel paziente neoplastico: aspetti clinici e terapeutici. Upjohn, Caponago, MilanoGoogle Scholar
  14. 14.
    Scevola D, Barbarini G, Zambelli A et al (1989) Nutritional status in AIDS patients, 5th edn. Int Conf AIDS, Abs Book, Montreal, p 465.Google Scholar
  15. 15.
    Scevola D, Zambelli A, Bottari G et al (1990) Problemi nutrizionali nella infezione-malattia da HIV. Alim Nutr Metab 11:159–170Google Scholar
  16. 16.
    Scevola D, Barbarini G, Zambelli A et al (1990) Evaluation and therapy of malnutrition in enteropathogenic AIDS, 6th edn. Int Conf AIDS, Abs Book, San Francisco, p 168Google Scholar
  17. 17.
    Scevola D, Zambelli A, Franchini A et al (1990) AIDS enteropatico: quadri endoscopici. Giorn Ital End Dig 13:93–103Google Scholar
  18. 18.
    Scevola D, Barbarini G, Bottari G et al (1990) Nutritional management of enteropathogenic human immunodeficiency virus infection. Eur J Gastroent Hepat 2:S100–S101Google Scholar
  19. 19.
    Dworkin MS, Williamson JM (2003) Adult/Adolescent spectrum of HIV disease project. AIDS wasting syndrome: trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndrome 33:267–273CrossRefGoogle Scholar
  20. 20.
    Marquart KH, Muller HA, Sailer J, Moser R (1985) Slim disease (AIDS). Lancet 2:186–187Google Scholar
  21. 21.
    Serwadda D, Mugerwa RD, Sevankambo NK et al (1985) Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet 2:849–852PubMedCrossRefGoogle Scholar
  22. 22.
    Kotler DP, Tierney AR, Francisco A et al (1989) The magnitude of body cell mass depletion determines the timing of death from wasting in AIDS. Am J Clin Nutr 50:444–447PubMedGoogle Scholar
  23. 23.
    Chlebowski RT, Grosvenor MB, Bernhard NH et al (1989) Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 84:1288–1293PubMedGoogle Scholar
  24. 24.
    Kotier DP, Tierney AR, Dilmanian FA et al (1991) Correlation between total body potassium and total body nitrogen in patients with acquired immunodeficiency syndrome. Clin Res 39:649AGoogle Scholar
  25. 25.
    Scevola D, Barbarini G, Bottari G et al (1991) Prevalence, etiology and management of AIDS malnutrition, 7th edn. Int Conf AIDS, WB 2169, FlorenceGoogle Scholar
  26. 26.
    Kotler DP, Rosenbaum KB, Wang J et al (1998) Alterations in body fat distribution in HIV-infected men and women, 12th edn. World AIDS Conference, Geneva, Switzerland, June-July, Abs 32173Google Scholar
  27. 27.
    Kotler DP, Rosenbaum K, Wang J, Pierson R (1999) Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Human Retrovirol 20:228–237Google Scholar
  28. 28.
    Gray GE, Gray LK (1980) Anthropometric measurements and their interpretations: principles, practice and problems. J Am Diet Assoc 77:534–539PubMedGoogle Scholar
  29. 29.
    Blackburn GC, Bistrian BR, Maini BS et al (1977) Nutritional and metabolic assessment of the hospital patient. J Parenter Enterai Nutr 31:11–22Google Scholar
  30. 30.
    Clouse RE (1983) The role of body weight in nutritional evaluation. Clin Consult 3:1Google Scholar
  31. 31.
    O’Sullivan P, Linke RA, Dalton S (1985) Evaluation of body weight and nutritional status among AIDS patients. J Am Diet Ass 85:1483–1484Google Scholar
  32. 32.
    Brennan MF (1977) Uncomplicated starvation versus cancer cachexia. Cancer Res 37:2359–2364PubMedGoogle Scholar
  33. 33.
    Grunfeld C, Kotier D, Hamadeh R et al (1989) Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 86:27–31PubMedCrossRefGoogle Scholar
  34. 34.
    Grunfeld C, Kotler DP (1992) Wasting in the acquired immunodeficiency syndrome, seminars in liver disease. Thieme, New YorkGoogle Scholar
  35. 35.
    Douglas RG, Shaw JHF (1989) Metabolic response to sepsis and trauma. Br J Surg 76:115–122PubMedCrossRefGoogle Scholar
  36. 36.
    Tisdale MJ (1991) Cancer cachexia. Br J Cancer 63:337–342PubMedGoogle Scholar
  37. 37.
    Beisel WR, Powanda MC (2003) Metabolic effects of infection on protein and energy status. J Nutr 133:3225–3275Google Scholar
  38. 38.
    Heymsfield SB, McManus C, Smith J et al (1982) Anthropometric measurement of muscle mass: revised equations for calculating bone-free arm musle area. Am J Clin Nutr 36:680–690PubMedGoogle Scholar
  39. 39.
    Anonymous (2004) WHO, 57th edn. World Health Assembly 22 May 2004 and Document A57/4Google Scholar
  40. 40.
    Scevola D, Bottari G, Faggi A et al (1994) Palliative care in infectious diseases. Eur J Pall Care 1:88–91Google Scholar
  41. 41.
    Scevola D, Bottari G, Oberto L, Faggi A (1996) AIDS cachexia: basics and treatment. In: Ruf B, Pohle HD, Goebel FD, L’age M (eds) HIV-Infektion, Pathogenese, Diagnostik und Therapie. Socio-medico Verlag, Graefelfing, pp 281–327Google Scholar
  42. 42.
    Scevola D, Bottari G, Oberto L et al (1996) Problemi nutrizionali del paziente AIDS e stratégie terapeutiche. Quaderni di Cure Palliative (Sl):51–64Google Scholar
  43. 43.
    Carrot Top Nutrition Resources (1988) Nutrition handbook for AIDS. Carrot Top Nutrition Resources, AuroraGoogle Scholar
  44. 44.
    Anonymous (1989) Task Force on Nutrition Support in AIDS. Guidelines for nutrition support in AIDS. Nutrition 5:39–46Google Scholar
  45. 45.
    Raiten DJ (1990) Nutrition and HIV infection. LSRO, FASEB, BethesdaGoogle Scholar
  46. 46.
    Anonymous (1994) ADA Reports. Position of the American Dietetic Association and the Canadian Dietetic Association: nutrition intervention in the care of persons with human immunodeficiency virus infection. J Am Diet Assoc 94:1042–1045CrossRefGoogle Scholar
  47. 47.
    King AB (1990) Malnutrition in HIV infection: prevalence, etiology and management. PAAC Notes 2:122–159Google Scholar
  48. 48.
    Sharkey SJ, Sharkey KA, Sutherland LR et al (1992) Nutritional status and food intake in human immunodeficiency virus infection. J Acquir Immune Defic Syndrome 5:1091–1098Google Scholar
  49. 49.
    Scevola D, Grossi P, Zambelli A (1987) L’endoscopia nella diagnosi della patologia associata all’AIDS. In: Aiuti F, Moroni M, Pocchiari F (eds) AIDS e sindromi correlate. Monduzzi Editore, Bologna, pp 211–214Google Scholar
  50. 50.
    Scevola D (1992) La patologia anorettale nell’AIDS.. In: Bianchi-Porro G, Parente F (eds) Le manifestazioni gastroenterologiche in corso di AIDS. Edizioni Libreria Cortina, Verona, pp 143–156Google Scholar
  51. 51.
    Scevola D, De Rysky C (1992) La patologia orofaringea nell’AIDS.. In: Bianchi-Porro G, Parente F (eds), Le manifestazioni gastroenterologiche in corso di AIDS. Edizioni Libreria Cortina, Verona, pp 29–41Google Scholar
  52. 52.
    Scevola D (1994) Patologia d’organo. Apparate gastrointestinale. In: Dianzani F, Ippolito G, Moroni M (eds) II libro italiano dell’AIDS. McGraw-Hill, Milano,pp 305–312Google Scholar
  53. 53.
    Scevola D (1998) Patologie del canale digerente, enterocoliti, e diarree infettive. In: Dianzani F, Ippolito G, Moroni M (eds). AIDS 1998. II contributo italiano. Piccin Nuova Libraria, Padova, pp 345–354Google Scholar
  54. 54.
    Nahler BL, Chu SY, Nwanyanwu C et al (1993) HIV wasting syndrome in the United States. AIDS 7:183–188CrossRefGoogle Scholar
  55. 55.
    Ullrich R, Zeitz M, Heise W et al (1989) Small intestinal structure and function in patients infected with human immunodeficiency virus (HIV): evidence for HIV-induced enteropathy. Ann Intern Med 111:15–21PubMedGoogle Scholar
  56. 56.
    Rondanelli EG (1989) AIDS: clinical and laboratory Atlas. EMP, PaviaGoogle Scholar
  57. 57.
    Gorbach SL, Knox TA, Roubenoff R (1993) Interactions between nutrition and infection with human immunodeficiency virus. Nutr Rev 8:226–234Google Scholar
  58. 58.
    Grunfeld C (1991) Mechanisms of wasting in infection and cancer: an approach to cachexia in AIDS. In: Kotler DP (ed) Gastrointestinal and nutritional manifestations of AIDS. Raven Press, New York, pp 207–229Google Scholar
  59. 59.
    Matsuyama T, Kobayashi N, Yamamoto N (1991) Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 5:1405–1417PubMedCrossRefGoogle Scholar
  60. 60.
    Melchior JC, Salmon D, Rigaud D et al (1991) Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 53:437–441PubMedGoogle Scholar
  61. 61.
    Bogden JD, Baker H, Frank O et al (1990) Micronutrient status and HIV infection. Ann NY Acad Sci 587:189–195PubMedGoogle Scholar
  62. 62.
    Coodley G (1990) Nutritional deficiency and AIDS. Ann lnt Med 113:807Google Scholar
  63. 63.
    Coodley GO, Loveless MO, Nelson HD, Coodley MK (1994) Endocrine dysfunction in the HIV wasting syndrome. J Acquir Immune Defic Syndr 7:46–51PubMedGoogle Scholar
  64. 64.
    Timbo BB, Tollefson L (1994) Nutrition: a cofactor in HIV disease. J Am Diet Assoc 94:1019–1022CrossRefGoogle Scholar
  65. 65.
    Baum MK, Shor-Posner G (1997) Nutritional status and survival in HIV-1 disease. AIDS 11:689–690PubMedGoogle Scholar
  66. 66.
    Scevola D, Bottari G, Zambelli A et al (1992) Trattamento dietetico ed ormonale dei deficit nutrizionali nell’AIDS. Clin Dietol 19:127–140Google Scholar
  67. 67.
    McMurray DN, Loomis SA, Casazza LJ et al (1981) Development of impaired cell-mediated immunity in mild and moderate malnutrition. Am J Clin Nutr 34:68–77PubMedGoogle Scholar
  68. 68.
    Bistrian BR, Blackburn GL, Scrimshaw NS, Fatt JP (1975) Cellular immunity in semistarved states in hospitalized adults. Am J Clin Nutr 28:1148–1155PubMedGoogle Scholar
  69. 69.
    Chandra RK (1988) Nutritional regulation of immunity. In: Chandra RK (ed) Nutrition and immunology. Alan R Liss, New York, pp 1–7Google Scholar
  70. 70.
    Moseson M, Zelenivnch-Jacquotte A, Belsito DV et al (1989) The potential role of nutritional factors in the induction of immunologic abnormalities in HIV-positive homosexual men. J Acquir Immune Defic Syndrome 2:235–247Google Scholar
  71. 71.
    Prasad C, Chandra RK (1991) Nutrition and immunity. In: Kotler DP (ed) Gastro intestinal and nutritional manifestations of AIDS. Raven Press, New York, pp 35–49Google Scholar
  72. 72.
    Heber D (1995) Pathophysiology of cancer/HIV malnutrition. In: Nutrition in cancer and HIV infection. Symp. N 8, 19th ed. Clinical Congress ASPEN, Miami Beach, Florida, pp 200–205Google Scholar
  73. 73.
    Grunfeld C, Pang M, Shimizu L et al (1992) Resting energy expenditure, caloric intake and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 55:455–460PubMedGoogle Scholar
  74. 74.
    Hellerstein MK, Meydani SN, Meydani M et al (1989) Interleukin-1 induced anorexia in the rat. J Clin Invest 84:228–235PubMedCrossRefGoogle Scholar
  75. 75.
    Hellerstein MK, Kahn J, Mudie H, Viteri F (1990) Current approach to the treatment of human immunodeficiency virus-associated weight loss: pathophysiologic considerations and emerging management strategies. Semin Oncol 17:17–33PubMedGoogle Scholar
  76. 76.
    Hoffman EP, Nader GA (2004) Balancing muscle hypertrophy and atrophy. Nat Med 6:584–585CrossRefGoogle Scholar
  77. 77.
    Grunfeld C, Feingold KR (1992) Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 5:329–337Google Scholar
  78. 78.
    Wolfe RR, Shaw JHF, Durkot MJ (1985) Effect of sepsis on VLDL kinetics: responses in basal state and during glucose infusion. Am Physiol 248:E732–E740Google Scholar
  79. 79.
    Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB (1989) Interleukin-6 immunoreactivity in human tumors. Am J Pathol 135:427–433PubMedGoogle Scholar
  80. 80.
    Singer P, Katz DP, Dillon L et al (1992) Nutritional aspects of the acquired immunodeficiency syndrome. Am J Gastroenterol 87:265–273PubMedGoogle Scholar
  81. 81.
    Nerad JL, Gorbach SL (1994) Nutritional aspects of HIV infection. Infect Dis Clin North Am 8:499–515PubMedGoogle Scholar
  82. 82.
    Feingold KR, Soued M, Serio MK et al (1989) Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 125:267–274PubMedCrossRefGoogle Scholar
  83. 83.
    Feingold KR, Adi S, Staprans I et al (1990) Diet affects the mechanisms by which TNF stimulates hepatic triglyceride production. Am J Physiol 259:E177–E184PubMedGoogle Scholar
  84. 84.
    Scevola D, Zambelli A, Bottari G et al (1991) Appetite stimulation and body weight gain with medroxyprogesterone acetate in AIDS anorexia and cachexia. Farmaci e Terapia 3:77–83Google Scholar
  85. 85.
    Beutler B, Cerami A (1986) Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320:584–588PubMedCrossRefGoogle Scholar
  86. 86.
    Beutler B, Cerami A (1986) Recombinant inter-leukin-1 suppresses lipoprotein lipase activity in 3T3-LI cells. J Immunol 135:3969–3971Google Scholar
  87. 87.
    Mullen BJ, Harris RBS, Patton JS, Martin RJ (1990) Recombinant tumor necrosis factor-alfa chronically administered in rats: lack of cachectic effect. Proc Soc Exp Biol Med 193:318–325PubMedGoogle Scholar
  88. 88.
    Feingold KR, Doerrler W, Dinarello CA et al (1992) Stimulation of lipolysis in cultured fat cells by TNF, IL-1 and the interferons is blocked by inhibition of prostaglandin synthesis. Endocrinology 130:10–16PubMedCrossRefGoogle Scholar
  89. 89.
    Feingold KR, Soued M, Serio MK et al (1990) The effect of diet on tumor necrosis factor timulation of hepatic lipogenesis. Metabolism 39:623–632PubMedCrossRefGoogle Scholar
  90. 90.
    Karmali RA, Chao CC, Basu A, Modak M (1989) Effect of n-3 and n-6 fatty acids on mammary H ras expression and PGE2 levels in DMBA-treated rats. Anticancer Res 9:1169–1174PubMedGoogle Scholar
  91. 91.
    Mora S, Pessin JE (2002) An adipocentric view of signaling and intracellular trafficking. Diabetes Metab Res Rev 18:345–356PubMedCrossRefGoogle Scholar
  92. 92.
    Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alfa: direct role in obesity-linked insulin resistance. Science 259:87–91PubMedCrossRefGoogle Scholar
  93. 93.
    Fried SK, Bunkin DA, Greenberg AS (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukine-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847–850PubMedCrossRefGoogle Scholar
  94. 94.
    Zhang Y, Proenca R, Maffei M et al (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432PubMedCrossRefGoogle Scholar
  95. 95.
    Faggioni R, Feingold KR, Grunfeld C (2001) Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 15:2565–2571PubMedCrossRefGoogle Scholar
  96. 96.
    Yamauchi T, Kamon J, Waki TH et al (2001) The fatderived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946PubMedCrossRefGoogle Scholar
  97. 97.
    Tsao TS, Lodish HF, Fruebis J (2002) ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 440:213–221PubMedCrossRefGoogle Scholar
  98. 98.
    Ailhaud G, Grimaldi P, Nègrel R (1992) Cellular and molecular aspects of adipose tissue development. Ann Rev Nutr 12:207–233CrossRefGoogle Scholar
  99. 99.
    Sugihara H, Yonemitsu N, Toda S et al (1988) Unilocular fat cells in three-dimensional collagen gel matrix culture. J Lipid Res 29:691–698PubMedGoogle Scholar
  100. 100.
    Ailhaud G, Amri EZ, Grimaldi P (1996) Fatty acids and expression of lipid-related genes in adipose cells. Proc Nutr Soc 55:151–154PubMedCrossRefGoogle Scholar
  101. 101.
    Digito M, D’Incau F et al (1996) Release of mitogenic factors by cultured preadipocytes from patients with multiple symmetric lipomatosis. Intern J Obes Relat Metab Disord 20:38Google Scholar
  102. 102.
    Bjorntorp P (1996) The regulation of adipose tissue distribution in humans. Intern J Obes Relat Metab Disord 20:291–302Google Scholar
  103. 103.
    Bjorntorp P (1993) Visceral obesity: a’Civilisation syndrome. ’Obes Res 1:206–222Google Scholar
  104. 104.
    Xu X, De Pergola G, Bjorntorp P (1990) The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology 126:1229–1234PubMedGoogle Scholar
  105. 105.
    Enzi G, Pavan M, Digito M et al (1993) Clustering of metabolic abnolmalities and other risk factors for cardiovascular disease in visceral obesity. Diab Nutr Metab 6:47–55Google Scholar
  106. 106.
    Cannon B, Jacobsson A, Rehnmark S, Nedergaard J (1996) Signal transduction in brown adipose tissue recruitment: noradrenaline and beyond. Intern J Obes Relat Metab Disord 3:S36–S42Google Scholar
  107. 107.
    Enzi G, Biondetti PR, Fiore D, Mazzoleni F (1982) Computed tomography of deep fat masses in multiple symmetric lipomatosis. Radiology 144:121–124PubMedGoogle Scholar
  108. 108.
    Enzi G, Favaretto L, Martini R et al (1983) Metabolic abnormalities in multiple symmetric lipomatosis. Elevated lipoprotein lipase activity in adipose tissue with hyperalfalipo-proteinemia. J Lipid Res 24:566–574PubMedGoogle Scholar
  109. 109.
    Enzi G (1984) Multiple symmetric lipomatosis: an update clinical report. Medicine 63:56–64PubMedCrossRefGoogle Scholar
  110. 110.
    Zancanaro C, Sbarbati A, Morroni M et al (1990) Multiple symmetric lipomatosis. Ultrastructural investigation of the tissue and preadipocytes in primary culture. Lab Invest 63:253–258PubMedGoogle Scholar
  111. 111.
    Melchior JC, Niyongabo T, Henzel D et al (1999) Malnutrition and wasting, immunodepression, and chronic inflammation as independent predictors of survival in HIV-infected patients. Nutrition 15:865–869PubMedCrossRefGoogle Scholar
  112. 112.
    Wheeler DA, Gibert CL, Launer CA et al (1998) Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 18:80–85PubMedGoogle Scholar
  113. 113.
    Smit E, Skolasky RL, Dobs AS et al (2002) Changes in the incidence and predictors of wasting syndrome related to human immunodeficiency virus infection, 1987–1999. Am J Epidemiol 156:211–218PubMedCrossRefGoogle Scholar
  114. 114.
    Wanke CA, Silva M, Knox TA et al (2000) Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 31:803–805PubMedCrossRefGoogle Scholar
  115. 115.
    Wanke CA, Silva M, Ganda A et al (2003) Role of acquired immune deficiency syndrome—defining conditions in human immunodeficiency virus-associated wasting. Clin Infect Dis 37(Suppl 2):S81–S84PubMedCrossRefGoogle Scholar
  116. 116.
    Carr A, Samaras K, Burton S et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51–F58PubMedCrossRefGoogle Scholar
  117. 117.
    Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral liopdystrophy, hyperlipidemia, and insulin resistance. Lancet 352:1881–1883CrossRefGoogle Scholar
  118. 118.
    Lo JC, Mulligan K, Tai VW et al (1998) ‘Buffalo hump’ in men with HIV-infection. Lancet 351:867–870PubMedCrossRefGoogle Scholar
  119. 119.
    Carr A, Samaras K, Thorisdottir A et al (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyper-lipidaemia, and diabetes mellitus; a cohort study. Lancet 353:2093–2099PubMedCrossRefGoogle Scholar
  120. 120.
    Carr A, Miller J, Law M, Cooper DA (2000) A syndrome of lipoatrophy, lactic acidaemia and live dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14:F25–F32PubMedCrossRefGoogle Scholar
  121. 121.
    Chen D, Misra A, Garg A (2002) Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 87:4845–4856PubMedCrossRefGoogle Scholar
  122. 122.
    Bernasconi E (1999) Metabolic effects of protease inhibitor therapy. AIDS Read 9:254–269PubMedGoogle Scholar
  123. 123.
    Bernasconi E, Boubaker K, Junghans C et al (2002) Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs. J Acquir Immune Defic Syndrome 31:50–55Google Scholar
  124. 124.
    Galli M, Cozzi-Lepri A, Ridolfo AL et al (2002) Incidence of adipose tissue alterations in first-line antiretroviral therapy. Arch Intern Med 162:2621–2628PubMedCrossRefGoogle Scholar
  125. 125.
    Salomon J, de Truchis P, Melchior JC (2002) Body composition and nutritional parameters in HIV and AIDS patients. Clin Chem Lab Med 40:1329–1333PubMedCrossRefGoogle Scholar
  126. 126.
    Jain RG, Furfine ES, Pedneault P et al (2001) Metabolic complications associated with antiretroviral therapy. Antiviral Res 51:151–177PubMedCrossRefGoogle Scholar
  127. 127.
    Dubè MP, Sattler FR (1998) Metabolic complications of antiretroviral therapies. AIDS Clin Care 10:41–44PubMedGoogle Scholar
  128. 128.
    Miller KD, Jones E, Yanovski JA et al (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351:871–875PubMedCrossRefGoogle Scholar
  129. 129.
    Rosenberg HE, Mulder J, Sepkowitz K et al (1998) ‘Protease-paunch’ in HIV+ persons receiving protease inhibitor therapy: incidence, risks and endocrinologic evaluation, 5th ed. Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998, Abstract 408Google Scholar
  130. 130.
    Sullivan AK, Nelson MR (1997) Marked hyperlipidaemia on ritonavir. AIDS 11:938–939PubMedCrossRefGoogle Scholar
  131. 131.
    Hengel RL, Watts NB, Lennox JL (1997) Benign symmetric lipomatosis associated with protease inhibitors. Lancet 350:1596PubMedCrossRefGoogle Scholar
  132. 132.
    Carr A, Emery S, Law M et al (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361:726–735PubMedCrossRefGoogle Scholar
  133. 133.
    Carr A, Law M (2003) An objective lipodystrophy severity grading scale derived from lipodystropy case definition score. J Acquir Immune Defic Syndr 33:571–576PubMedCrossRefGoogle Scholar
  134. 134.
    Tien PC, Grunfeld C (2004) What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 17:27–32PubMedCrossRefGoogle Scholar
  135. 135.
    European Paediatric Lipodystrophy Group (2004) Antiretroviral therapy, fat redistribution and hyper-lipidaemia in HIV-infected children in Europe. AIDS 18:1443–1451CrossRefGoogle Scholar
  136. 136.
    Durnin JV, Womersley J (1974) Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 37:77–97CrossRefGoogle Scholar
  137. 137.
    Scevola D, Marinelli M (1991) Dietetica medica. Edizioni Medico Scientifiche, PaviaGoogle Scholar
  138. 138.
    Boulier A, Fricker J, Thomasset AL et al (1990) Fat-free mass estimation by the two-electrode impedance method. Am J Clin Nutr 52:581–585PubMedGoogle Scholar
  139. 139.
    Ott M, Fischer H, Polat H et al (1995) Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 9:20–25PubMedGoogle Scholar
  140. 140.
    Mallon P, Miller J, Cooper D, Carr A (2003) Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS 17:971–979PubMedCrossRefGoogle Scholar
  141. 141.
    Nolan D, Hammond E, James I et al (2003) Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 8:617–626PubMedGoogle Scholar
  142. 142.
    Engelson ES, Kotler DP, Tan YX et al (1999) Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 69:1162–1169PubMedGoogle Scholar
  143. 143.
    Saag M, Tien P, Gripshover B et al (2003) Body composition in HIV infected men with and without peripheral lipoatrophy is different than controls. In: Conference on retroviruses and opportunistic infections, 10th ed. CCO, Boston, p 320Google Scholar
  144. 144.
    Enzi G, Gasparo M, Biondetti PR et al (1986) Subcutaneous and visceral fat distribution accordino to sex, age, and overweight, evaluated by computer tomography. Am J Clin Nutr 44:739–746PubMedGoogle Scholar
  145. 145.
    Saint-Marc T, Partisani M, Poizot-Martin I et al (2000) Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 14:37–49PubMedCrossRefGoogle Scholar
  146. 146.
    Martinez E, Bianchi L, Garcia-Viejo MA et al (2000) Sonographic assessment of regional fat in HIV-1infected people. Lancet 356:1412–1413PubMedCrossRefGoogle Scholar
  147. 147.
    Behrens GMN, Stoll M, Schmidt RE (2000) Lipodystrophy syndrome in HIV infection. Drug Saf 1:57–76CrossRefGoogle Scholar
  148. 148.
    Garg A (2004) Acquired and inherited lipodystrophies. N Engl J Med 350:1220–1234PubMedCrossRefGoogle Scholar
  149. 149.
    Gervasoni C, Ridolfo AL, Trifirö G et al (1999) Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 13:465–471PubMedCrossRefGoogle Scholar
  150. 150.
    Kakuda TN (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22:685–708PubMedCrossRefGoogle Scholar
  151. 151.
    Boyle BA (1999) Lipodystrophy: a new phenomeneon? AIDS Reader 9:15–17PubMedGoogle Scholar
  152. 152.
    Nolan D, John M. Mallal S (2001) Antiretroviral therapy and the lipodystrophy syndrome. Part 2: Concepts in aetiopathogenesis. Antivir Ther 6:145–160PubMedGoogle Scholar
  153. 153.
    Bastard JP, Caron M, Vidal H et al (2002) Association between altered expression of adipogenic factor SREBP-1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359:1026–1031PubMedCrossRefGoogle Scholar
  154. 154.
    Ranganathan S, Kern PA (2002) The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. J Endocrinol 172:155–162PubMedCrossRefGoogle Scholar
  155. 155.
    Baril L, Idhammou A, Beucler I et al (1999) Are the decreased lipolytic enzyme activities responsible for the hypertriglyceridemia in Pi-treated patients. 6th Conference on retroviruses and opportunistic infections, Chicago, III/1999, Abs 664Google Scholar
  156. 156.
    Solerte SB, Rondanelli M, Fioravanti M et al (1995) Impaired regulation of GH-IGF-1-IGFBP3 axis and ACTH-adrenal function in AIDS patients (CDC IVC) with wasting syndrome. A possible defensive mechanism. J Endocrinol Invest 18:43Google Scholar
  157. 157.
    Scevola D, Oberto L, Bottari G, Faggi A (1995) Lipidi e malattie infettive. Abs Book XII Congresso Nazionale ADI, Torino 16–18/11/1995, p 187Google Scholar
  158. 158.
    Lewis W, Dalakas MC (1995) Mitochondrial toxicity of antiviral drugs. Nat Med 1:417–422PubMedCrossRefGoogle Scholar
  159. 159.
    Brinkman K, Smeitink JA, Reiss P (1999) Mitochondria toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354:1112–1115PubMedCrossRefGoogle Scholar
  160. 160.
    Mynarcik DC, Combs T, McNurlan MA et al (2002) Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 31:514–520PubMedGoogle Scholar
  161. 161.
    Lindegaard B, Keller P, Bruunsgaard H et al (2004) Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIVinfected patients. Clin Exp Immunol 135:273–279PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Daniele Scevola
    • 1
  • Angela Di Matteo
    • 1
  • Omar Giglio
    • 2
  • Filippo Uberti
    • 1
  1. 1.Department of Infectious Diseases, IRCCS S.Matteo PolyclinicUniversity of PaviaPaviaItaly
  2. 2.Department of Infectious DiseasesUniversity of Pavia, IRCCS Policlinico S.MatteoPaviaItaly

Personalised recommendations